Zoetis balance sheet
At the end of fiscal 2025, Zoetis had total assets of $15.49bn, total liabilities of $12.07bn and shareholders' equity of $3.42bn. It held $2.45bn in cash against $9.15bn of debt: net debt of $6.70bn.
Balance sheet
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.1 | 0.3 | 0.6 | 0.9 | 1.2 | 0.7 | 1.6 | 1.6 | 1.9 | 3.6 | 3.5 | 3.6 | 2.0 | 2.0 | 2.5 | 1.5 |
| Receivables | — | 0.9 | 1.1 | 1.0 | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.0 | 1.1 | 1.2 | 1.3 | 1.3 | 1.4 | 1.6 |
| Inventory | — | 1.3 | 1.3 | 1.3 | 1.5 | 1.5 | 1.4 | 1.4 | 1.4 | 1.6 | 1.9 | 2.3 | 2.6 | 2.3 | 2.5 | 2.6 |
| Total current assets | — | 2.9 | 3.4 | 3.5 | 3.8 | 3.4 | 4.2 | 4.4 | 4.7 | 6.6 | 6.9 | 7.5 | 6.3 | 6.0 | 6.8 | 6.4 |
| Goodwill | 1.0 | 1.0 | 1.0 | 1.0 | 1.5 | 1.5 | 1.5 | 2.5 | 2.6 | 2.7 | 2.7 | 2.7 | 2.8 | 2.7 | 2.8 | 2.8 |
| Total assets | — | 6.3 | 6.6 | 6.6 | 7.9 | 7.6 | 8.6 | 10.8 | 11.5 | 13.6 | 13.9 | 14.9 | 14.3 | 14.2 | 15.5 | 15.1 |
| Accounts payable | — | 0.3 | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.5 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 |
| Deferred revenue (current) | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — |
| Total current liabilities | — | 1.1 | 1.4 | 1.1 | 1.8 | 1.1 | 1.1 | 1.2 | 1.8 | 2.2 | 1.8 | 3.2 | 1.9 | 3.4 | 2.2 | 2.1 |
| Short-term debt | — | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 0.6 | 0.0 | 1.4 | 0.0 | 1.4 | 0.0 | — |
| Long-term debt | — | 0.0 | 3.6 | 3.6 | 4.5 | 4.5 | 5.0 | 6.4 | 5.9 | 6.6 | 6.6 | 6.6 | 6.6 | 5.2 | 9.0 | 9.0 |
| Total debt | 0.0 | 0.1 | 3.7 | 3.7 | 4.9 | 4.5 | 5.0 | 6.5 | 6.5 | 7.3 | 6.7 | 8.0 | 6.7 | 6.7 | 9.2 | 9.2 |
| Total liabilities | — | 2.2 | 5.6 | 5.3 | 6.8 | 6.2 | 6.8 | 8.6 | 8.8 | 9.8 | 9.4 | 10.5 | 9.3 | 9.5 | 12.1 | 11.9 |
| Shareholders' equity | 3.7 | 4.0 | 0.9 | 1.3 | 1.1 | 1.5 | 1.8 | 2.2 | 2.7 | 3.8 | 4.5 | 4.4 | 5.0 | 4.8 | 3.4 | 3.1 |
| Net debt (negative = net cash) | −0.1 | −0.2 | 3.0 | 2.8 | 3.7 | 3.8 | 3.4 | 4.9 | 4.6 | 3.6 | 3.2 | 4.4 | 4.6 | 4.7 | 6.7 | 7.7 |
| Shares outstanding | — | — | 500m | 501m | 497m | 493m | 486m | 480m | 476m | 475m | 473m | 464m | 458m | 448m | 425m | 414m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 1.4 | 1.3 | 1.4 | 1.5 | 1.5 | 1.4 | 1.5 | 1.6 |
| Inventory | 2.4 | 2.3 | 2.4 | 2.4 | 2.5 | 2.5 | 2.6 | 2.6 |
| Total current assets | 6.3 | 6.0 | 5.9 | 5.9 | 6.6 | 6.8 | 6.5 | 6.4 |
| Goodwill | 2.7 | 2.7 | 2.7 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 |
| Total assets | 14.4 | 14.2 | 14.1 | 14.5 | 15.2 | 15.5 | 15.2 | 15.1 |
| Accounts payable | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 |
| Total current liabilities | 1.7 | 3.4 | 3.4 | 3.4 | 1.8 | 2.2 | 2.1 | 2.1 |
| Short-term debt | 0.0 | 1.4 | 1.4 | 1.4 | 0.0 | 0.0 | — | — |
| Long-term debt | 6.6 | 5.2 | 5.2 | 5.2 | 7.1 | 9.0 | 9.0 | 9.0 |
| Total debt | 6.6 | 6.6 | 6.6 | 6.6 | 7.1 | 9.0 | 9.0 | 9.0 |
| Total liabilities | 9.1 | 9.5 | 9.4 | 9.5 | 9.8 | 12.1 | 11.9 | 11.9 |
| Shareholders' equity | 5.2 | 4.8 | 4.7 | 5.0 | 5.4 | 3.4 | 3.2 | 3.1 |
| Shares outstanding | 452m | 448m | 446m | 444m | 441m | 425m | 420m | 414m |
Compare with peers
- Bausch Health Companies Inc. balance sheet
- Haleon plc balance sheet
- Viatris balance sheet
- Organon & Co. balance sheet
- Universe Pharmaceuticals Inc balance sheet
Head to head: BHC vs ZTSHLN vs ZTSVTRS vs ZTSOGN vs ZTS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies